What Four Years Can Tell Us About Treating Moderate to Severe HS

Nicholas Brownstone, MD, walks us through the four-year efficacy and safety data for continuous secukinumab in moderate to severe hidradenitis suppurativa (HS), drawing directly from the SUNSHINE and SUNRISE core and extension trials. His overview focuses on clinically meaningful endpoints reported through Week 204, including sustained HiSCR responses over time, persistent reductions in draining tunnel count, and tolerability over four years of continuous treatment, which is especially relevant in a chronic, relapsing disease where patients often need long-term therapy.